Prometrium and Tadalafil Interaction: Safety, Risks, and Clinical Guidance

Why This Combination Comes Up in Clinical Practice

Prometrium is prescribed to millions of women receiving menopausal hormone therapy (HRT). The 2022 Hormone Therapy Position Statement from The Menopause Society confirms that micronized progesterone is the preferred progestogen for endometrial protection in women with an intact uterus taking estrogen. Tadalafil, meanwhile, holds FDA approval for erectile dysfunction (ED), benign prostatic hyperplasia (BPH), and pulmonary arterial hypertension (PAH) under the brand name Adcirca [1]. Overlap occurs in several real-world scenarios: postmenopausal women prescribed tadalafil off-label for sexual dysfunction or Raynaud phenomenon, transgender women on progesterone who also take tadalafil, and couples where a shared medicine cabinet prompts questions about accidental co-exposure. The clinical question is straightforward. Do these two drugs interfere with each other's metabolism, amplify side effects, or require dose changes?

Pharmacokinetic Interaction: CYP3A4 Overlap

Both Prometrium and tadalafil depend on cytochrome P450 3A4 for hepatic biotransformation, but their interaction at this enzyme is minimal in practice. According to the FDA-approved Prometrium label, micronized progesterone undergoes extensive first-pass metabolism via CYP3A4 and CYP2C19 to produce 5-alpha and 5-beta reduced metabolites [2]. The tadalafil prescribing information similarly identifies CYP3A4 as the primary enzyme responsible for its clearance [3].

Neither drug is a clinically relevant inhibitor or inducer of CYP3A4. Progesterone at physiologic and standard therapeutic concentrations does not meaningfully inhibit CYP3A4 activity, as demonstrated in human liver microsome studies published in Drug Metabolism and Disposition [4]. Tadalafil likewise shows no inhibition of CYP3A4 at therapeutic plasma levels, per its label [3]. Without either drug blocking the enzyme the other depends on, plasma concentrations of both remain within expected ranges during co-administration.

The risk scenario changes when a third agent enters the picture. Strong CYP3A4 inhibitors such as ketoconazole increased tadalafil AUC by 312% in a pharmacokinetic study [5]. The same class of inhibitors would simultaneously slow progesterone clearance. Clinicians should audit the full medication list for strong CYP3A4 inhibitors (ritonavir, itraconazole, clarithromycin) before dismissing this combination as benign.

Pharmacodynamic Interaction: Additive Vasodilation

The more relevant concern is pharmacodynamic, not pharmacokinetic. Progesterone has documented vasodilatory properties. A study in Hypertension showed that progesterone reduces systemic vascular resistance through endothelium-dependent nitric oxide release and calcium channel modulation [6]. Tadalafil lowers blood pressure by 1-2 mmHg on average through cyclic GMP-mediated smooth muscle relaxation in vascular beds, per data in the tadalafil clinical pharmacology section of its FDA label [3].

These effects are additive, not synergistic. The clinical magnitude is small in most patients. A healthy postmenopausal woman taking Prometrium 200 mg nightly with tadalafil 5 mg daily for BPH-related lower urinary tract symptoms might experience a 3-5 mmHg drop in systolic pressure beyond what either drug alone would cause. That drop matters most in patients already on antihypertensives or those with baseline systolic pressures below 110 mmHg.

This is distinct from the nitrate-tadalafil contraindication. Organic nitrates (nitroglycerin, isosorbide mononitrate) produce severe, potentially fatal hypotension when combined with PDE5 inhibitors because both massively amplify the cyclic GMP pathway [7]. Progesterone's vasodilatory mechanism is milder and operates through partially different signaling. No case reports in the FDA Adverse Event Reporting System (FAERS) database link the progesterone-tadalafil combination to clinically significant hypotensive episodes [8].

DDI Database Severity Ratings

Major drug interaction databases classify this pair as low-risk. Lexicomp, Micromedex, and Clinical Pharmacology do not flag a direct Prometrium-tadalafil interaction. The Drugs@FDA database lists no labeled contraindication or warning for this specific combination in either drug's prescribing information [9]. The absence of a flagged interaction reflects the pharmacokinetic reality: neither drug alters the other's exposure at standard doses.

For comparison, tadalafil carries explicit warnings against co-administration with nitrates (contraindicated) and alpha-blockers (dose-limit to 5 mg if combining with tamsulosin 0.4 mg) [3]. Prometrium's interaction profile primarily concerns CNS depressants (alcohol, benzodiazepines) due to its GABAergic metabolite allopregnanolone [2]. The two drugs inhabit different risk categories and do not compound each other's high-priority warnings.

Progesterone's GABAergic Sedation and Tadalafil Timing

Prometrium's oral formulation produces the neuroactive metabolite allopregnanolone, a positive allosteric modulator of GABA-A receptors. This is why the FDA label instructs patients to take Prometrium at bedtime and warns about drowsiness and dizziness [2]. Tadalafil can cause headache and dizziness in 11% and 3% of patients, respectively, per pooled clinical trial data submitted to the FDA [10].

When both drugs are taken in the evening, dizziness and somnolence may overlap. A practical framework for managing this:

Timing strategy: If tadalafil is used on-demand (10-20 mg before sexual activity), separate it from the Prometrium dose by 2-3 hours. Take Prometrium at bedtime as labeled; take tadalafil earlier in the evening. If tadalafil is prescribed daily (2.5-5 mg for BPH), morning dosing avoids the sedation window entirely.

First-dose monitoring: Patients starting both drugs simultaneously should check seated and standing blood pressure during the first week. A systolic drop exceeding 20 mmHg on standing warrants reassessment.

Alcohol interaction: Both drugs interact with alcohol. Progesterone plus alcohol deepens sedation [2]. Tadalafil plus alcohol may amplify orthostatic hypotension [3]. The three-way combination (progesterone, tadalafil, alcohol) should be approached with caution.

Dose Adjustments: When They Apply

No dose reduction is required for either Prometrium or tadalafil when used together at standard doses. The American College of Obstetricians and Gynecologists (ACOG) recommends micronized progesterone 200 mg/day for 12-14 days per cycle (sequential regimen) or 100 mg/day continuously for endometrial protection [11]. These doses remain appropriate regardless of tadalafil co-administration.

Tadalafil dosing follows its approved ranges: 10-20 mg on-demand for ED, 2.5-5 mg daily for ED or BPH, or 40 mg daily (as Adcirca) for PAH [3]. The only scenario requiring dose adjustment is the addition of a strong CYP3A4 inhibitor, which would warrant reducing tadalafil to no more than 2.5 mg daily or 5 mg every 72 hours per the label [3].

Patients with hepatic impairment deserve extra attention. Both drugs rely on hepatic metabolism. The Prometrium label recommends caution in liver disease because reduced clearance raises progesterone and allopregnanolone levels [2]. Tadalafil exposure increases in patients with Child-Pugh Class A or B cirrhosis, and the drug is not recommended in Child-Pugh Class C [3]. Co-prescribing both in moderate hepatic impairment requires closer monitoring even though the direct drug-drug interaction is minimal.

Special Populations

Transgender women: Progesterone is increasingly used in feminizing hormone therapy, though evidence for breast development benefits remains limited. A 2019 review in Transgender Health noted that progesterone's role in transgender care lacks strong trial data but is commonly prescribed at 100-200 mg nightly [12]. Transgender women may also use tadalafil for sexual function. The interaction profile is the same as in cisgender populations. Standard monitoring applies.

Older adults: Women over 65 taking Prometrium as part of HRT face increased sedation risk from allopregnanolone [2]. The Beers Criteria from the American Geriatrics Society flag medroxyprogesterone but not micronized progesterone specifically, though caution with any sedating agent in older adults is warranted [13]. Tadalafil pharmacokinetics are not significantly altered by age alone [3], but the additive hypotension risk is clinically more relevant in patients over 65 who may have orthostatic instability.

Renal impairment: Prometrium does not require renal dose adjustment [2]. Tadalafil clearance decreases in severe renal impairment (CrCl <30 mL/min), and the starting dose should be limited to 5 mg for on-demand use with a maximum frequency of once every 72 hours [3].

Monitoring Recommendations

A structured monitoring approach for patients on both medications:

1. Baseline blood pressure before starting the combination. Recheck at 1 week and 1 month.
2. Symptom assessment for dizziness, lightheadedness, or excessive daytime drowsiness at follow-up visits.
3. Medication reconciliation at every visit, specifically screening for CYP3A4 inhibitors, nitrates, and alpha-blockers that could amplify risks.
4. Hepatic function (ALT, AST) if either drug is newly started in a patient with known liver disease, per AASLD guidance on drug-induced liver injury surveillance [14].
5. Patient education on recognizing orthostatic hypotension symptoms and avoiding sudden position changes, particularly in the first 2 hours after taking both medications.

What the Evidence Does Not Show

No randomized controlled trial has directly studied co-administration of micronized progesterone and tadalafil. The safety assessment relies on pharmacokinetic principles, shared metabolic pathway analysis, individual drug safety profiles, and absence of adverse event signals in post-marketing surveillance. This is typical for drug pairs without a mechanistic basis for serious interaction. The FDA's guidance on clinical drug interaction studies does not recommend dedicated interaction trials for substrate-substrate pairs that lack mutual inhibition [15].

The clinical bottom line: Prometrium and tadalafil can be prescribed together. Monitor blood pressure, separate evening doses when possible, and audit for CYP3A4 inhibitors that could change the risk calculus.